Cosciens Biopharma Inc (CSCIF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 9,587 | 7,143 | 5,640 | 5,260 | 3,652 |
| Cost of Goods | 4,858 | 4,205 | 157 | 90 | 2,317 |
| Gross Profit | 4,729 | 2,938 | 5,483 | 5,170 | 1,335 |
| Operating Expenses | 19,610 | 7,772 | 20,893 | 13,931 | 7,358 |
| Operating Income | -14,023 | -4,629 | -15,253 | -8,671 | -5,706 |
| Interest Expense | 129 | 136 | 3 | 21 | 736 |
| Other Income | -1,073 | 395 | -7,471 | 215 | 1,719 |
| Pre-tax Income | -15,225 | -4,370 | -22,727 | -8,477 | -4,723 |
| Income Tax | 84 | -885 | N/A | -109 | 395 |
| Net Income Continuous | -15,309 | -3,485 | -22,727 | -8,368 | -5,118 |
| Net Income | $-15,309 | $-3,485 | $-22,727 | $-8,368 | $-5,118 |
| EPS Basic Total Ops | -5.93 | -1.89 | -18.72 | -7.28 | -12.00 |
| EPS Basic Continuous Ops | -5.93 | -1.89 | -18.72 | -7.28 | -12.46 |
| EPS Diluted Total Ops | -5.93 | -1.89 | -18.72 | -7.28 | -12.00 |
| EPS Diluted Continuous Ops | -5.93 | -1.89 | -18.72 | -7.28 | -12.46 |
| EPS Diluted Before Non-Recurring Items | -5.93 | -13.64 | -11.84 | -7.00 | -12.00 |
| EBITDA(a) | $-13,272 | $-3,186 | $-16,822 | $-10,196 | $-4,217 |